These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19194361)

  • 1. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
    Kantarjian H
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors: the next generation.
    Fricker J
    Lancet Oncol; 2006 Aug; 7(8):621. PubMed ID: 16900596
    [No Abstract]   [Full Text] [Related]  

  • 4. 10 years of progress in chronic myelogenous leukemia.
    Jabbour E; Mathisen MS; O'Brien S
    J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803
    [No Abstract]   [Full Text] [Related]  

  • 5. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
    Kimura S
    Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S; Sawyer S
    JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
    [No Abstract]   [Full Text] [Related]  

  • 8. As leukemia options grow, drugs jockey to be first-line therapies.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment for de novo chronic myeloid leukemia in chronic phase].
    Hirase C; Matsumura I
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():298-303. PubMed ID: 23133971
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chronic myeloid leukemia 2008].
    Cervantes F
    Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
    Hampton T
    JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
    [No Abstract]   [Full Text] [Related]  

  • 13. Two new agents effective in Gleevec-resistant CML.
    Cancer Biol Ther; 2004 Dec; 3(12):1198-9. PubMed ID: 15864854
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of imatinib-intolerant or -resistant CML patients].
    Kimura S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():304-8. PubMed ID: 23133972
    [No Abstract]   [Full Text] [Related]  

  • 15. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
    Liu H; Chen XG
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546
    [No Abstract]   [Full Text] [Related]  

  • 16. [State of the art in the treatment of chronic leukemias].
    Ohnishi K
    Rinsho Ketsueki; 2006 Apr; 47(4):278-86. PubMed ID: 16715962
    [No Abstract]   [Full Text] [Related]  

  • 17. 3. Imatinib therapy in chronic myelogenous leukemia.
    Jinnai I
    Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
    [No Abstract]   [Full Text] [Related]  

  • 18. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 20. Circumventing resistance to kinase-inhibitor therapy.
    Druker BJ
    N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.